Over the past year and a half, many of you followed the AIDS.gov blog post series Future Directions for NIAID HIV Research by Dr. Carl Dieffenbach, Director of the Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID) at NIH. Last week, NIAID advanced those efforts by issuing several requests for applications (RFAs)…
NIAID Advances Efforts to Restructure Clinical Trials Networks with Funding Announcements
February 3, 2012 • 0 comments • By Miguel Gomez, Director, AIDS.gov, and Senior Communications Advisor, Office of HIV/AIDS Policy, U.S. Department of Health and Human Services
6th International AIDS Society Conference Underway This Week
July 18, 2011 • 0 comments • By Miguel Gomez, Director, AIDS.gov, and Senior Communications Advisor, Office of HIV/AIDS Policy, U.S. Department of Health and Human Services
This week, over 5,000 delegates from around the world are attending the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) in Rome, Italy. This biannual conference is the world’s largest open scientific conference on HIV/AIDS, and provides “a unique opportunity for the world’s leading scientists, clinicians, public health experts and…
HIV Vaccine Awareness Day, 2011
May 17, 2011 • 1 comment • By Anthony Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health
Cross-posted from Office of National AIDS Policy Blog
Cross-posted from Office of National AIDS Policy Blog
Co-authored by Margaret (Peggy) Johnston, Ph.D., Senior Scientific Consultant, NIAID.
HIV Vaccine Awareness Day provides an opportunity to acknowledge the more than 35,000 individuals who have volunteered for preventive HIV vaccine trials over the past 25 years. Without their participation, the modest success that we have achieved…
Using Pre-Exposure Prophylaxis (PrEP) as a Prevention Tool for MSM: The Promise Comes with Challenges
February 27, 2011 • 5 comments • By Ronald Valdiserri, M.D., M.P.H., Deputy Assistant Secretary for Health, Infectious Diseases, and Director, Office of HIV/AIDS Policy, U.S. Department of Health and Human Services
On Saturday, February 26th, I attended a day-long meeting organized by the Centers for Disease Control and Prevention (CDC) and hosted by the Fenway Community Health Center in Boston. The theme of the meeting was “Moving forward with PrEP Implementation.” Meeting participants included researchers involved in the original iPrEX study and other ongoing HIV prevention…
President Obama Welcomes New HIV Prevention Research Results
November 23, 2010 • 7 comments • By AIDS.gov
Cross-posted from The White House, Office of the Press Secretary
Cross-posted from The White House, Office of the Press Secretary
WASHINGTON, D.C. – Today, the National Institutes of Health announced findings on recent HIV prevention research. The study finds that a daily dose of an oral antiretroviral drug taken by HIV-negative gay and bisexual men reduced the risk of acquiring HIV infection by 43.8 percent, and had even higher rates of effectiveness, up to 73…
NIH-Led Scientists Find Antibodies that Prevent Most HIV Strains from Infecting Human Cells
July 30, 2010 • 4 comments • By Laura Sivitz, National Institute of Allergy and Infectious Diseases, NIH
Scientists have discovered two potent human antibodies that can stop more than 90 percent of known global HIV strains from infecting human cells in the laboratory. The scientists also have demonstrated how one of these disease-fighting proteins accomplishes this feat. According to the scientists, these antibodies could be used to design improved HIV vaccines, or…
International AIDS Conference Day 3: Research Highlights
July 20, 2010 • 0 comments • By Ronald Valdiserri, M.D., M.P.H., Deputy Assistant Secretary for Health, Infectious Diseases, and Director, Office of HIV/AIDS Policy, U.S. Department of Health and Human Services
Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, shared the latest scientific information with the conference delegates about the actual steps that the human immunodeficiency virus (HIV) takes when it makes contact with the human genital tract (through exposure to semen or vaginal secretions) which result in infection.Understanding, in detail,…
Renewed Hope for an HIV Vaccine
In late September, the U.S. federal government announced news on HIV vaccine research that sparked interest around the world. A trial called RV144, or the Thai HIV vaccine clinical trial , showed that the experimental vaccine regimen was safe and about 31 percent effective in preventing HIV infection. Although the vaccine regimen had a very…